Zydus Lifesciences is focussing on top 30 molecules, said Sharvil Patel, managing director, on Wednesday, adding that the company expects double-digit growth for India.
Recommended Articles
View All
Budget 2023 — Let the opposition use today's session effectively sans typical disruption tactics
Feb 1, 2023 IST5 Min(s) Read
Budget 2023: From improved GST structure to inverted duty reforms, the EV sector want a mega growth push
Jan 31, 2023 IST3 Min(s) Read
India's Economic Survey shifts the narrative to 'quality of life'
Jan 31, 2023 IST3 Min(s) Read
Budget 2023: Prioritising defence and innovation
Jan 31, 2023 IST4 Min(s) Read
In an interview to CNBC-TV18, he said, “At the stage, we are at now with a focus on the top 30 molecules with the new introductions on the proprietary molecule side, we are poised to deliver better than market growth and double-digit growth for India formulations business and we are confident of doing so.”
Talking about US business, he said that it has always been a cyclical business and it should be seen in a 3-5 year window. “We believe that any good company with a strong portfolio, good cost, position, good backward integration can continue to do well in the US generics markets,” said Patel.
He further said that the company expects generic launches in the next 18 months to aid US business and it should scale up to USD 1 billion revenue range through these launches.
For more details, watch the accompanying video